News & Events
Bora Pharmaceuticals to Expand Rare Disease Portfolio with Acquisition of US-Based Pyros Pharmaceuticals
Taipei, Taiwan, October 25, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today...
Bora Appoints J.D. Mowery As First Division President Of Its CDMO Business
Bora Appoints J.D. Mowery As First Division President Of Its CDMO Business TAIPEI, TAIWAN, October 3, 2024 –...
Tanvex Appoints Biopharma Industry Veteran Stephen Lam as CEO
Taipei, Taiwan - September 4, 2024 - Tanvex BioPharma, Inc. (“Tanvex” or “the Company”, TWSE: 6541), the...
Bora Pharmaceuticals Makes a Strategic Investment into Tanvex to Provide Global BioManufacturing Services.
Taipei, Taiwan, August 27, 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today...
2024 CPHI Milan
We are attending 2024 CPHI Milan and are excited to discuss how our new capabilities and our comprehensive global...
Bora Completes Acquisition of US Sterile Fill/Finish Facility From Emergent
TAIPEI, TAIWAN, August 20th 2024 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), a a global...
Bora Recognized with Dual Accolades at Asia Best Companies to Work for Awards 2024
《HR Asia》, the leading HR magazine in Asia, recently announced the winners of the 2024 “The HR Asia Best Companies to Work for in Asia Awards.” Bora Pharmaceuticals stood out among nearly 370 participating companies, not only winning the prestigious HR Asia Best Companies to Work for in Asia Taiwan 2024 award for the second time but also receiving the HR Asia Most Caring Company Awards 2024, recognizing its commitment to the “People First” philosophy since its inception as one of the core competences of the Bora Group.
Bio Asia-Taiwan 2024
We are attending Bio Asia-Taiwan 2024 in Taipei! Do you want to make success more certain? Connect with our team at the event!
Bora Pharmaceuticals Expands North American Footprint with Agreement to Acquire First Sterile Manufacturing Facility
Bora Pharmaceuticals announced it entered into an agreement for Emergent BioSolutions’ sterile manufacturing facility in Baltimore-Camden, Maryland as part of a major commercial expansion for the Company.